1stOncology™: Cancer Intelligence Service – Page 15514 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018

On March 20, 2018 Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, reported that CEO and President Werner Cautreels, Ph.D., will be presenting at the 17th Annual Needham Healthcare Conference in New York City at 9:30 a.m. ET on Tuesday, March 27, 2018 (Press release, Selecta Biosciences, MAR 20, 2018, View Source [SID1234524913]). A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference

On March 20, 2018 RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, reported that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, on Monday, April 9, 2018, at 11:05 am CET, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco (Press release, RedHill Biopharma, MAR 20, 2018, View Source [SID1234524912]).

A live audio of the presentation will be available on the Company’s website at: View Source A copy of the presentation will be available on the Company’s website and a replay of the webcast will be available on the Company’s website for a period of 30 days.

OncBioMune Announces Presentation at the 2018 AACR Annual Meeting

On March 20, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, reported that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois (Press release, Oncbiomune, MAR 20, 2018, View Source [SID1234524911]).

The clinical trial abstract, entitled "Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients," highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study. Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively.

The abstract also will be published online in the 2018 Proceedings of the AACR (Free AACR Whitepaper).

Details of the abstract are as follows:

Session Title: Phase I Clinical Trials 2
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 14

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

On March 20, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 17, to review first-quarter results. Dominic Caruso, Executive Vice President, Chief Financial Officer; Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Joseph J. Wolk, Vice President, Investor Relations, will host the call (Press release, Johnson & Johnson, MAR 20, 2018, View Source [SID1234524910]).

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on April 25, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13677626.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference

On March 20, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present a corporate update at the 17th Annual Needham Healthcare Conference in New York on Tuesday, March 27 at 9:00 a.m. ET (Press release, Aeglea BioTherapeutics, MAR 20, 2018, View Source [SID1234524909]).

To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.